Qingkesha^® Posaconazole Enteric-coated Tablets are a new-generation triazole antifungal drug, widely used for the prevention and treatment of invasive fungal diseases. Like the injection formulation, it works by inhibiting CYP450-dependent 14α-demethylase, blocking the synthesis of ergosterol, and disrupting the fungal cell membrane biosynthesis, altering its permeability and inhibiting fungal growth. Qingkesha^® Posaconazole Enteric-coated Tablets were approved for market as a Class 4 chemical drug in July 2023 and are listed as a Category B product under the national medical insurance program. Compared to other triazole drugs, Posaconazole has a broad antifungal spectrum, high tissue concentration, unique pharmacokinetics, good safety profile, and fewer drug interactions, making it the first-line drug recommended in both domestic and international guidelines for the prevention and treatment of invasive fungal diseases.